DexCom, Inc. (NASDAQ:DXCM) Position Increased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,241,701 shares of the medical device company’s stock after buying an additional 80,740 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in DexCom were worth $278,173,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of DXCM. Stableford Capital II LLC lifted its stake in DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after buying an additional 88 shares during the last quarter. Valley National Advisers Inc. lifted its position in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. FORVIS Wealth Advisors LLC grew its position in DexCom by 0.7% in the 4th quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after purchasing an additional 110 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its stake in shares of DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after purchasing an additional 115 shares during the period. Finally, HM Payson & Co. raised its holdings in shares of DexCom by 8.5% during the third quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock valued at $138,000 after buying an additional 116 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on DXCM shares. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Thursday. UBS Group lifted their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Citigroup increased their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Finally, Raymond James boosted their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $141.67.

DexCom Price Performance

Shares of DXCM opened at $127.42 on Thursday. The business’s 50-day moving average is $132.94 and its 200-day moving average is $121.16. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The company has a market capitalization of $50.67 billion, a price-to-earnings ratio of 82.21, a P/E/G ratio of 2.19 and a beta of 1.23. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Equities research analysts expect that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insider Activity

In related news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 629 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the transaction, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The disclosure for this sale can be found here. In the last quarter, insiders have sold 190,004 shares of company stock valued at $25,610,270. Insiders own 0.41% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.